Climb Bio (CLYM) Other financing activities (2024 - 2026)

Climb Bio (CLYM) posted Other financing activities of $5000.0 for Q1 2026, down 100.0% on a QoQ basis from $108.8 million in Q4 2024.

Climb Bio (CLYM) Other financing activities (2024 - 2026) Analysis & Trends

Climb Bio's Other financing activities history runs 2 years deep, the most recent figure standing at $5000.0 for Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5000.0 (down 100.0% YoY) and the FY2024 annual result came in at $119.8 million, changed N/A from the prior year.
Other financing activities was $5000.0 for Q1 2026 at Climb Bio, down from $108.8 million in the prior quarter.
Across five years, Other financing activities topped out at $119.7 million in Q2 2024 and bottomed at $5000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Climb Bio	870.33 Mn	870.33 Mn	-

Download Data